Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q1

2784.TEDINET S100OYAV
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥657.1bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥2.59T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥643.6bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.1bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥3.8bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥3.7bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥32.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.7bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥3.6bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥4.6bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥32.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.2bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥2.2bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥3.2bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥1.33Tat 2022-06-30Cons.Assets
Total assets¥1.30Tat 2022-03-31Cons.Assets
Total assets¥1.34Tat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥852.5bnat 2022-06-30Cons.Liabilities
Total liabilities¥832.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥475.5bnat 2022-06-30Cons.Net assets
Net assets / equity¥471.8bnat 2022-03-31Cons.Net assets
Net assets / equity¥486.2bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥178.2bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥180.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥10.52022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥153.572021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.322021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio35.8%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥82m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥585.4bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥580.9bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.9bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥207m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥92m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥59.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥59.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥142m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥664.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥657.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥7.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥7.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30¥126m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥567.7bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥563.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥4.2bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥3.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥11.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.2bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2.8bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥534m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥8.4bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥8.4bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2021-04-01 → 2021-06-30−¥272m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥63.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥63.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥113m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥444m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥650.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥643.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥7.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥3.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 376
ItemContextValueUnit
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember63567000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember11078000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember8369000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember650704000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-7117000000JPY
Net salesPrior1YTDDuration643586000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember3013000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember444000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember534000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember-272000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember3720000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember126000000JPY
Operating incomePrior1YTDDuration3846000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember580932000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember59475000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember7863000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember8850000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember657122000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration657122000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember4507000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember142000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember3096000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember7745000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-7745000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember585439000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember59617000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember10959000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember8850000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember664868000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-7745000000JPY
Net salesCurrentYTDDuration657122000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember2443000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember448000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E02962-000ManufacturingBusinessReportableSegmentsMember207000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E02962-000MedicalRelatedBusinessReportableSegmentsMember-92000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember3006000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember82000000JPY
Operating incomeCurrentYTDDuration3088000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-08-12
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第20期第１四半期(自 2022年４月１日　至 2022年６月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)アルフレッサ ホールディングス株式会社
Company name in english cover pageFilingDateInstantAlfresa Holdings Corporation
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　荒川　隆治
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都千代田区大手町一丁目１番３号

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass